Home/Filings/4/0001209191-20-046330
4//SEC Filing

Flynn Daniel Lee 4

Accession 0001209191-20-046330

CIK 0001654151other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 4:00 PM ET

Size

7.9 KB

Accession

0001209191-20-046330

Insider Transaction Report

Form 4
Period: 2020-08-10
Flynn Daniel Lee
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-08-109,0290 total
    Exercise: $1.89Exp: 2025-12-17Common Stock (9,029 underlying)
  • Exercise/Conversion

    Common Stock

    2020-08-10$1.89/sh+9,029$17,065237,475 total
Holdings
  • Common Stock

    (indirect: By Trust)
    91,020
Footnotes (1)
  • [F1]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates.

Issuer

Deciphera Pharmaceuticals, Inc.

CIK 0001654151

Entity typeother

Related Parties

1
  • filerCIK 0001713712

Filing Metadata

Form type
4
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 4:00 PM ET
Size
7.9 KB